Homocysteine and fracture risk in postmenopausal women: the OFELY study
- 111 Downloads
Homocysteine has recently been described as an independent risk factor for osteoporotic fractures in the elderly. We prospectively followed 671 postmenopausal women belonging to the OFELY study, mean age 62 years, during a mean follow-up of 10 years. After adjustment for age, there was no significant relation between the plasma level of homocysteine and the subsequent risk of fracture.
Plasma homocysteine increases with age. Recent studies have described homocysteine as an independent risk factor for osteoporotic fractures in elderly. We investigated the role of plasma homocysteine in the subsequent risk of fractures in healthy ambulatory postmenopausal women.
Homocysteine was measured at baseline in 671 postmenopausal women from the OFELY cohort (mean age 62.2 ± 9 years). Incident clinical fractures were recorded during annual follow-up and vertebral fractures were evaluated with radiographs every four years. A cox proportional hazards model based on time to first fracture was used to calculate hazard ratios for quartiles of homocysteine values.
Mean homocysteine was 10.6 ± 3.4 μmol/l, increasing with age. After adjustment for age, homocysteine was significantly associated with physical activity, calcium intake, serum albumin and serum creatinine but not with bone turnover markers and bone mineral density. During a mean follow-up of 10 years, 183 fractures occurred among 134 women. After adjustment for age, the overall relative risk of fracture for each 1 SD increment of homocysteine was 1.03 (95%CI 0.87–1.31). Fracture risk was higher in women with homocysteine in the highest quartile without adjustment but no longer after adjustment for age.
Homocysteine is not an independent risk factor of osteoporotic fractures in healthy postmenopausal women from the OFELY cohort with a broad age range.
KeywordsFracture Homocysteine Osteoporosis Postmenopausal women Risk
- 1.(2001) NIH consensus development panel on osteoporosis. JAMA 285:758–779Google Scholar
- 4.World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva, Switzerland, pp 1–129Google Scholar
- 5.Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRefGoogle Scholar
- 10.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
- 22.Quéré I, Simorre B, Ruivard M, Le Hello C, Parrot F, Mégnien JL, Touati G, Chassé JF, Saudubray JM, Zittoun J (2001) Homocystinuria in adulthood. Rev Med Int 22:347–355Google Scholar
- 26.Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot L, Hofman A, Witteman JCM, van Leeuwen JPTM, Breteler MMB, Lips P, Pols HAP, Uitterlinden AG (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033–2041PubMedCrossRefGoogle Scholar
- 31.Lubec B, Fang-Kicher S, Lubec T, Blom HJ, Boers GHJ (1996) Evidence for McKusick’s hypothesis of deficient collagen cross-linking in patients with homocystinuria. Bioch Biophys Act 1315:159–162Google Scholar
- 32.Sakamoto W, Isomura H, Fujie K, Deyama Y, Kato A, Nishihira J, Izumi H (2005) Homocysteine attenuates the expression of osteocalcin but enhances osteopontin in MC3T3-E1 preosteoblastic cells. Bioch Biophys Act 1740:12–16Google Scholar
- 40.Refsum H, Nurk E, Smith D, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygard O, Vollset SE (2006) The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136:1731–1740Google Scholar
- 43.Woodside JV, Yarnell JWG, McMaster D, Young IS, Harmon DL, McCrum EE, Patterson CC, Gey KF, Whitehead AS, Evans A (1998) Effect of B-group vitamins and antioxidants vitamins on hyperhomocysteinemia: a double-blind, randomised, factorial-design, controlled trial. Am J Clin Nutr 67:858–865PubMedGoogle Scholar